Severe Asthma Market Snapshot: A Competitive Therapy Area That Will Test Payers' Influence
Executive Summary
Several biologic drugs are now available for the 10% of asthma patients with severe uncontrolled disease, and Dupixent could join them later this year, setting the therapy area up for a competitive showdown.
You may also be interested in...
Keeping Track: First RMAT Approval On The Horizon; Big Weeks For Merck, Lilly And Celgene
The latest drug development news and highlights from our US FDA Performance Tracker.
Sanofi Genzyme's Sibold On Investing In Blood Disorders And Fending Off Rivals
Sibold talked to Scrip about launching the blood clotting disorder drug Cablivi and finding room in a competitive hemophilia market.
ICER On Asthma Biologics: 50%-79% Price Discounts Needed To Meet Value Assessment Metrics
The independent value assessment organization’s draft assessment found that the prices for all five marketed biologics for severe asthma – Xolair, Nucala, Cinqair, Fasenra and Dupixent – far exceed standard cost-effectiveness thresholds.